Arrowhead Pharmaceuticals, Inc. (ARWR) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
ARWR Revenue Growth
ARWR Revenue Analysis (2014–2025)
As of May 8, 2026, Arrowhead Pharmaceuticals, Inc. (ARWR) generated trailing twelve-month (TTM) revenue of $622.0 million, reflecting significant decline in growth of -86.4% year-over-year. The most recent quarter (Q2 2026) recorded $73.7 million in revenue, down 72.1% sequentially.
Looking at the longer-term picture, ARWR's 5-year compound annual growth rate (CAGR) stands at +56.6%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $829.4 million in 2025, representing a new all-time high.
When compared to Healthcare sector peers including ALNY (+82.6% YoY), NTLA (+16.9% YoY), and BEAM (+108.0% YoY), ARWR has underperformed the peer group in terms of revenue growth. Compare ARWR vs ALNY →
ARWR Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| ARWRCurrent | $622M | -86.4% | +56.6% | 11.9% | |
 ALNY | $3.7B | +82.6% | +49.8% | 13.5% | |
 NTLA | $68M | +16.9% | +3.1% | -651.7% | |
 BEAM | $140M | +108.0% | +466.3% | -274.6% | |
 SRPT | $2.2B | -2.2% | +32.4% | -29.9% | |
 IONS | $944M | +47.5% | +5.3% | -40.5% |
ARWR Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $829.4M | +23258.2% | $805.5M | 97.1% | $98.3M | 11.9% |
| 2024 | $3.6M | -98.5% | $-15,044,000 | -423.7% | $-601,080,000 | -16927.1% |
| 2023 | $240.7M | -1.0% | $228.2M | 94.8% | $-205,002,000 | -85.2% |
| 2022 | $243.2M | +75.9% | $232.8M | 95.7% | $-178,507,000 | -73.4% |
| 2021 | $138.3M | +57.2% | $0 | - | $-149,036,000 | -107.8% |
| 2020 | $88.0M | -47.9% | $0 | - | $-93,159,000 | -105.9% |
| 2019 | $168.8M | +945.7% | $0 | - | $61.2M | 36.3% |
| 2018 | $16.1M | -48.6% | $0 | - | $-55,936,235 | -346.5% |
| 2017 | $31.4M | +19736.5% | $0 | - | $-36,995,909 | -117.8% |
| 2016 | $158K | -58.6% | $0 | - | $-81,742,726 | -51627.1% |
Full ARWR Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
See ARWR's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ARWR Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ARWR vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonARWR — Frequently Asked Questions
Quick answers to the most common questions about buying ARWR stock.
Is ARWR's revenue growth accelerating or slowing?
ARWR revenue declined -86.4% year-over-year, contrasting with the 5-year CAGR of +56.6%. TTM revenue fell to $622M. This reverses the prior growth trend.
What is ARWR's long-term revenue growth rate?
Arrowhead Pharmaceuticals, Inc.'s 5-year revenue CAGR of +56.6% reflects the variable expansion pattern. Current YoY growth of -86.4% is below this long-term average.
How is ARWR's revenue distributed by segment?
ARWR reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.